A Postdoctoral position in the areas of cancer cell biology, metabolism, and endolysosomal trafficking is available immediately in the Edinger lab at the University of California, Irvine. The Applicant would participate in studies investigating strategies to target macropinocytosis in cancer cells as means to limit tumor growth and overcome resistance to approved therapies. For more information on the Edinger lab, please visit https://edingerlab.bio.uci.edu/.
The project will entail confocal microscopy, basic molecular biology approaches, and tumor studies in mice. Applicants who have recently obtained a PhD and have experience in these areas are especially encouraged to apply. American citizens and permanent residents are eligible for positions on the Cancer Biology and Therapeutics NCI-supported T32 training grant. Successful applicants will be self-motivated, have a strong record of productivity, and a passion for science. Irvine is located near the coast, mid-way between Los Angeles and San Diego. UC Irvine is the home of the NCI-designated Chao Family Comprehensive Cancer Center and hosts a strong community of collaborative, interdisciplinary researchers interested in cancer cell biology. The collegial atmosphere at UCI facilitates collaboration, and the successful applicant will need to work effectively as a part of a scientific team.
Qualified candidates should submit their curriculum vitae, a cover letter including short summary of past research accomplishments/future goals, and the names and contact information of three references to the following on-line recruitment URL:
Applications will be considered until the position is filled.
The University of California, Irvine is an Equal Opportunity/Affirmative Action Employer advancing inclusive excellence. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, age, protected veteran status, or other protected categories covered by the UC nondiscrimination policy.
Close Date 3/31/2020